Aquestive Therapeutics (AQST) Non-Current Assets (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Non-Current Assets of $10.9 million for Q1 2026, down 16.25% year-over-year from $13.1 million in Q1 2025, and down 1.92% quarter-over-quarter from $11.2 million in Q4 2025.
Aquestive Therapeutics (AQST) Non-Current Assets (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Non-Current Assets history runs 10 years deep, the most recent figure standing at $10.9 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 16.25% year-over-year to $10.9 million; the TTM figure through Mar 2026 stood at $46.0 million (down 13.69% YoY), while the FY2025 annual figure was $11.2 million, down 15.51% from the prior year.
- Non-Current Assets for Q1 2026 stood at $10.9 million, down from $11.2 million in the prior quarter.
- The five-year high for Non-Current Assets was $17.6 million in Q1 2023, with the low at $10.9 million in Q1 2026.
- The 5-year median for Non-Current Assets is $13.6 million (2024), against an average of $14.2 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets jumped 34.37% in 2023, then fell 21.21% in 2024.
- Aquestive Therapeutics' Non-Current Assets stood at $17.2 million in 2022, then decreased by 4.25% to $16.5 million in 2023, then decreased by 19.74% to $13.2 million in 2024, then fell by 15.51% to $11.2 million in 2025, then retreated by 1.92% to $10.9 million in 2026.
- Business Quant data shows AQST's Non-Current Assets at $10.9 million in Q1 2026, $11.2 million in Q4 2025, and $11.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Aquestive Therapeutics | 560.60 Mn | 560.60 Mn | 9.80 Mn | 13.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.61 Mn |
| Mar 31, 2026 | 10.94 Mn |
| Dec 31, 2025 | 11.16 Mn |
| Sep 30, 2025 | 11.89 Mn |
| Jun 30, 2025 | 11.98 Mn |
| Mar 31, 2025 | 13.07 Mn |
| Dec 31, 2024 | 13.20 Mn |
| Sep 30, 2024 | 13.39 Mn |
| Jun 30, 2024 | 13.59 Mn |
| Mar 31, 2024 | 16.14 Mn |
| Dec 31, 2023 | 16.45 Mn |
| Sep 30, 2023 | 16.99 Mn |
| Jun 30, 2023 | 17.21 Mn |
| Mar 31, 2023 | 17.58 Mn |
| Dec 31, 2022 | 17.18 Mn |
| Sep 30, 2022 | 13.76 Mn |
| Jun 30, 2022 | 12.81 Mn |
| Mar 31, 2022 | 13.94 Mn |
| Dec 31, 2021 | 14.73 Mn |
| Sep 30, 2021 | 15.08 Mn |